Cytosorbents Corporation (CTSO) Financials

CTSO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 38.0 million 38.7 million
March 31, 2026 40.6 million 38.4 million
Dec. 31, 2025 44.2 million 38.3 million
Sept. 30, 2025 45.8 million 36.7 million

CTSO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -1.8 million 912000
March 31, 2026 -1.2 million 544000
Dec. 31, 2025 -4.9 million 1.5 million
Sept. 30, 2025 -2.6 million 488000

CTSO Net Income

No data available :(

CTSO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 4.4 million 11.6 million 12.2 million
March 31, 2026 4.8 million 11.8 million 12.3 million
Dec. 31, 2025 6.2 million 16.7 million 12.4 million
Sept. 30, 2025 7.5 million 14.6 million 12.6 million

CTSO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 62.8 million
March 31, 2026 62.7 million
Dec. 31, 2025 62.8 million
Sept. 30, 2025 62.8 million

CTSO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 25000 1.5 million 8.0 million -
March 31, 2026 11000 1.0 million 8.1 million -
Dec. 31, 2025 62883 1.2 million 9.4 million -
Sept. 30, 2025 17000 918000 8.6 million -

CTSO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 9.6 million 2.6 million
March 31, 2026 8.9 million 2.7 million
Dec. 31, 2025 9.2 million 2.4 million
Sept. 30, 2025 9.5 million 2.8 million

CTSO Revenue by Segment
Graph available only for paid members. Upgrade to see it.

CTSO

Price: $3.79

52 week price:
3.66
20.00

Payout Ratio Range:
-466.81%
95.83%

Earnings Per Share: -0.29 USD

Exchange: NCM

Sector: Healthcare

Industry: Medical Devices

Country: United States

Volume: 305200

Ebitda: -2.1 million

Market Capitalization: 12.2 million

Links: